623 related articles for article (PubMed ID: 26350096)
21. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
Green S; Trejo CL; McMahon M
Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
[TBL] [Abstract][Full Text] [Related]
22. HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
Ghosh A; Lai C; McDonald S; Suraweera N; Sengupta N; Propper D; Dorudi S; Silver A
Exp Mol Pathol; 2013 Feb; 94(1):103-8. PubMed ID: 22982087
[TBL] [Abstract][Full Text] [Related]
23. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
24. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
25. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
Park KS; Yang H; Choi J; Seo S; Kim D; Lee CH; Jeon H; Kim SW; Lee DH
Cancer Lett; 2017 Oct; 406():47-53. PubMed ID: 28797845
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic KRAS promotes malignant brain tumors in zebrafish.
Ju B; Chen W; Orr BA; Spitsbergen JM; Jia S; Eden CJ; Henson HE; Taylor MR
Mol Cancer; 2015 Feb; 14(1):18. PubMed ID: 25644510
[TBL] [Abstract][Full Text] [Related]
27. The end of KRAS, and other, cancers? A new way forward.
Mallucci L; Wells V
Drug Discov Today; 2014 Apr; 19(4):383-7. PubMed ID: 24291216
[TBL] [Abstract][Full Text] [Related]
28. Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation.
Martin ES; Belmont PJ; Sinnamon MJ; Richard LG; Yuan J; Coffee EM; Roper J; Lee L; Heidari P; Lunt SY; Goel G; Ji X; Xie Z; Xie T; Lamb J; Weinrich SL; VanArsdale T; Bronson RT; Xavier RJ; Vander Heiden MG; Kan JL; Mahmood U; Hung KE
Clin Cancer Res; 2013 Jun; 19(11):2929-40. PubMed ID: 23403635
[TBL] [Abstract][Full Text] [Related]
29. RAS-mediated oncogenic signaling pathways in human malignancies.
Khan AQ; Kuttikrishnan S; Siveen KS; Prabhu KS; Shanmugakonar M; Al-Naemi HA; Haris M; Dermime S; Uddin S
Semin Cancer Biol; 2019 Feb; 54():1-13. PubMed ID: 29524560
[TBL] [Abstract][Full Text] [Related]
30. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
31. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
32. Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
Kuracha MR; Thomas P; Loggie BW; Govindarajan V
PLoS One; 2017; 12(6):e0179510. PubMed ID: 28640835
[TBL] [Abstract][Full Text] [Related]
33. KRASG12C inhibitor: combing for combination.
Chakraborty A
Biochem Soc Trans; 2020 Dec; 48(6):2691-2701. PubMed ID: 33242077
[TBL] [Abstract][Full Text] [Related]
34. PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine.
Davies EJ; Marsh Durban V; Meniel V; Williams GT; Clarke AR
J Pathol; 2014 May; 233(1):27-38. PubMed ID: 24293351
[TBL] [Abstract][Full Text] [Related]
35. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
36. Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in
Stewart A; Coker EA; Pölsterl S; Georgiou A; Minchom AR; Carreira S; Cunningham D; O'Brien ME; Raynaud FI; de Bono JS; Al-Lazikani B; Banerji U
Mol Cancer Ther; 2019 Aug; 18(8):1396-1404. PubMed ID: 31262731
[TBL] [Abstract][Full Text] [Related]
37. Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers.
Okumura S; Jänne PA
Clin Cancer Res; 2014 Aug; 20(16):4193-9. PubMed ID: 24907112
[TBL] [Abstract][Full Text] [Related]
38. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
39. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
[TBL] [Abstract][Full Text] [Related]
40. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
Hollestelle A; Elstrodt F; Nagel JH; Kallemeijn WW; Schutte M
Mol Cancer Res; 2007 Feb; 5(2):195-201. PubMed ID: 17314276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
